ATTOVIA THERAPEUTICS
Attovia Therapeutics is a biotherapeutics pipeline developer focused on immune-mediated illness and oncology. The company uses the nanobody platform to create tiny format binders with low picomolar affinity, increased selectivity, quicker internalization, and rapid tissue penetration, thereby assisting cancer patients' treatment.
ATTOVIA THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2023-01-01
Address:
Fremont, California, United States
Country:
United States
Website Url:
http://www.attovia.com
Total Employee:
11+
Status:
Active
Total Funding:
165 M USD
Technology used in webpage:
Euro Google Maps CrUX Top 50m CrUX Dataset Google Maps API Google Maps For Work
Similar Organizations
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Cabaletta Bio
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Chimeron Bio
Chimeron Bio develops agents for personalized cancer gene therapy.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Verismo Therapeutics
Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
Marshall Wace
Marshall Wace investment in Series B - Attovia Therapeutics
Redmile Group
Redmile Group investment in Series B - Attovia Therapeutics
Nextech Ventures
Nextech Ventures investment in Series B - Attovia Therapeutics
EcoR1 Capital
EcoR1 Capital investment in Series B - Attovia Therapeutics
Logos Capital
Logos Capital investment in Series B - Attovia Therapeutics
venBio Partners
venBio Partners investment in Series B - Attovia Therapeutics
Illumina Ventures
Illumina Ventures investment in Series B - Attovia Therapeutics
Goldman Sachs Asset Management
Goldman Sachs Asset Management investment in Series B - Attovia Therapeutics
Frazier Life Sciences
Frazier Life Sciences investment in Series B - Attovia Therapeutics
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Attovia Therapeutics
Official Site Inspections
http://www.attovia.com Semrush global rank: 9.82 M Semrush visits lastest month: 308
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Attovia Therapeutics"
Our Team - ATTOVIA
Prior to Attovia, Zaneta served full time at Frazier, focusing on company creation activities and advising on private and public investment opportunities. Before joining Frazier, Zaneta served …See details»
Attovia Therapeutics - Crunchbase Company Profile
Attovia develops biotherapeutics aimed at treating immune-mediated diseases through its proprietary ATTOBODY technology. The company focuses on …See details»
Attovia Therapeutics - LinkedIn
Attovia Therapeutics Biotechnology Research Fremont, California 3,300 followers Creating medicines for immune-mediated disease based on Attobody®, a novel biparatopic nanobody platform.See details»
Attovia 2025 Company Profile: Valuation, Funding
Attovia General Information Description. Developer of biotherapeutics pipeline designed for immune-mediated disease and oncology. The company …See details»
Attovia Therapeutics Org Chart + Executive Team - The Official …
Organizational Chart of Attovia Therapeutics. Attovia Therapeutics Org Chart www.attovia.com. has 15 executives +1 510 399 5001; Add an executive. Attovia Therapeutics News . Anything …See details»
Attovia Therapeutics - Leadership Team - The Org
The Leadership Team at Attovia Therapeutics is responsible for steering the company’s strategic vision and ensuring the successful development of innovative biotherapeutics. Comprised of …See details»
Attovia Therapeutics - Contacts, Employees, Board Members, …
Organization. Attovia Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. ... Attovia Therapeutics has 1 current employee profile, Chief …See details»
Attovia Therapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised ... Goldman Sachs Asset Management: Jun 20, …See details»
Careers - ATTOVIA
Join the Attovia team and leave a lasting imprint on medicine. We work together, celebrate our successes together, and learn together. At Attovia, we're more than a biotech startup - we're a catalyst for change Our strength isn't just in our …See details»
Zaneta Odrowaz - Chief Business Officer - Attovia Therapeutics
Dec 20, 2012 CBO at Attovia | Co-founder · Experience: Attovia Therapeutics · Education: The University of Manchester · Location: San Francisco · 500+ connections on LinkedIn. View …See details»
Attovia Therapeutics Launches with $60 Million Series A Financing …
Jun 20, 2023 Tao Fu, M.S., M.B.A., co-founder of Attovia and Venture Partner at Frazier Life Sciences, will serve as Attovia’s chief executive officer and join the Board. Mr. Fu is a …See details»
Attovia, a new California biotech, launches with plans to rethink …
Jun 20, 2023 Attovia aims to "fine-tune" antibody components to make more selective medicines, Fu said. Essentially, Attovia will use nanobodies, or small antibody fragments, to …See details»
Attovia Therapeutics Announces $90 Million Series C Financing to ...
5 days ago Attovia Therapeutics, Inc. Series C round led by Deep Track Capital with participation from additional new and existing investors. Financing will fund early-to-mid-stage …See details»
Attovia Enhances Clinical and Development Expertise with
Mar 26, 2024 Attovia Enhances Clinical and Development Expertise with Appointment of Chief Medical Officer and Clinical and Scientific Advisory Boards March 26, 2024 07:00 ET | Source: …See details»
Attovia secures $105m to advance lead programmes development
May 10, 2024 Attovia is also preparing to nominate a development candidate for ATTO-002 in late 2024 and aims to progress to IND next year. The company is advancing discovery-stage …See details»
Sanofi backs $90M financing for I&I biologic developer
5 days ago Attovia plans to evaluate its extended half-life bispecific for inflammatory skin conditions like atopic dermatitis, chronic spontaneous urticaria and prurigo nodularis. Over the …See details»
Attovia Therapeutics raises $90M to treat autoimmune diseases
5 days ago Attovia Therapeutics, a clinical-stage biopharma company developing treatments for autoimmune diseases, closed a $90 million Series C round. Why it matters: The financing, …See details»
News & Media - ATTOVIA
Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 …See details»
Attovia Therapeutics Announces $90 Million Series C ... - BioSpace
4 days ago “Attovia has created a transformative pipeline leveraging its revolutionary ATTOBODY platform,” said Rebecca Luse, Managing Director at Deep Track Capital. “We are …See details»
Attovia Therapeutics Announces $90 Million Series C Financing to ...
4 days ago Attovia is also advancing ATTO-3712, a first-in-class anti-IL13 x IL31, half-life extended bispecific designed to provide breakthrough efficacy and convenient dosing in atopic …See details»